HOLLISTER, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced the pricing of its underwritten public offering of 8,000,000 shares of its common stock at a price to the public of $5.00 per share.

加利福尼亚州霍利斯特，2026年10月20日（环球电讯社）——Alpha Teknova, Inc.（“Teknova”）（纳斯达克股票代码：TKNO）是一家领先的用于新型疗法、疫苗和分子诊断的发现、开发和商业化的关键试剂生产商，今日宣布其承销公开发行8,000,000股普通股的定价为每股5.00美元。

The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be $40 million. Teknova has also granted the underwriters a 30-day option to purchase up to 1,200,000 additional shares of its common stock. All of the shares of common stock in the offering are to be sold by Teknova.

在扣除承销折扣、佣金及发行费用之前，本次发行的预计募集资金总额为4,000万美元。Teknova还授予承销商一项为期30天的选择权，以购买最多1,200,000股额外的普通股。本次发行中的所有普通股均由Teknova出售。

The offering is expected to close on or about October 22, 2026, subject to the satisfaction of customary closing conditions..

预计此次发行将于2026年10月22日或前后完成，具体取决于惯例交割条件的满足情况。

TD Cowen and William Blair are acting as joint book-running managers for the proposed offering. Craig-Hallum is acting as lead manager. Stephens Inc. and Roth Capital Partners are acting as co-managers. Perrella Weinberg Partners is serving as financial adviser to Teknova.

TD Cowen 和 William Blair 担任本次拟议发行的联席账簿管理人。Craig-Hallum 担任主承销商。Stephens Inc. 和 Roth Capital Partners 担任副承销商。Perrella Weinberg Partners 担任 Teknova 的财务顾问。

Teknova currently intends to use the net proceeds from this offering for general corporate purposes, including potentially the repayment of outstanding debt obligations. Teknova may use a portion of the net proceeds to acquire or invest in other businesses, products, and technologies that are complementary to its own, although Teknova has no current commitments or arrangements to do so..

Teknova 目前打算将本次发行的净收益用于一般企业用途，包括可能偿还现有债务。Teknova 可能会使用部分净收益收购或投资于与其业务互补的其他企业、产品和技术，尽管 Teknova 目前没有为此做出任何承诺或安排。

The public offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-288613), previously filed with the Securities and Exchange Commission (the “SEC”) on July 10, 2025, and declared effective on July 16, 2025. The securities may be offered only by means of a prospectus and prospectus supplement that form a part of the registration statement.

本次公开发行是依据之前于2025年7月10日向美国证券交易委员会（“SEC”）提交，并于2025年7月16日生效的S-3表格 shelf 注册声明（文件编号：333-288613）进行的。证券仅可通过构成注册声明一部分的招股说明书和招股说明书补充文件进行发售。

A preliminary prospectus supplement and the accompanying prospectus relating to and describing the terms of the offering have been filed with the SEC and are available on the SEC’s website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus, and when available, copies of the final prospectus supplement and the accompanying prospectus relating to the offering, may also be obtained by contacting TD Securities (USA) LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by email at TDManualrequest@broadridge.com; or William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, Illinois 60606, by telephone at 1-800-621-0687, or by email at prospectus@williamblair.com..

初步招股说明书补充文件及随附的招股说明书（涉及并描述本次发行条款）已提交至美国证券交易委员会（SEC），并可在 SEC 网站 www.sec.gov 上获取。如需获取初步招股说明书补充文件及随附的招股说明书，以及在可用时获取与本次发行相关的最终招股说明书补充文件及随附的招股说明书的副本，也可通过以下方式联系：TD Securities (USA) LLC，收件人：Broadridge Financial Solutions，地址：1155 Long Island Avenue, Edgewood, New York 11717，电子邮箱：TDManualrequest@broadridge.com；或 William Blair & Company, L.L.C.，收件人：Prospectus Department，地址：150 North Riverside Plaza, Chicago, Illinois 60606，电话：1-800-621-0687，电子邮箱：prospectus@williamblair.com。

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction..

本新闻稿不构成出售要约或购买要约的招揽，也不得在任何州或司法管辖区进行这些证券的销售，如果在此类州或司法管辖区的证券法下，在注册或资格认定之前，此类要约、招揽或销售将是非法的。

About Teknova

关于Teknova

Teknova makes solutions possible. Since 1996, Teknova has been innovating the manufacture of critical reagents for the life sciences industry to accelerate the discovery and development of novel breakthroughs that will help people live longer, healthier lives. We offer fully customizable solutions for every stage of the workflow, supporting industry leaders in genomics, molecular diagnostics, and emerging therapeutic modalities.

Teknova 让解决方案成为可能。自 1996 年以来，Teknova 一直致力于创新生命科学行业关键试剂的制造工艺，以加速新型突破性成果的发现与开发，帮助人们拥有更长久、更健康的生活。我们为工作流程的每个阶段提供完全可定制的解决方案，支持基因组学、分子诊断以及新兴治疗模式领域的行业领导者。

Our fast turnaround of high-quality agar plates, microbial culture and cryopreservation media, buffers and reagents, and water helps our customers scale seamlessly from RUO to GMP. Headquartered in Hollister, California, with over 180,000 square feet of state-of-the-art facilities, Teknova’s modular manufacturing platform was designed by our team of scientists, engineers, and quality control experts to efficiently produce the foundational ingredients for the discovery and commercialization of next-generation therapies..

我们快速交付高质量的琼脂平板、微生物培养及冻存培养基、缓冲液和试剂以及水，帮助客户实现从研究用（RUO）到药品生产质量管理规范（GMP）的无缝规模化扩展。Teknova 总部位于加利福尼亚州霍利斯特，拥有超过 180,000 平方英尺的先进设施，其模块化制造平台由我们的科学家、工程师和质量控制专家团队设计，旨在高效生产用于下一代疗法发现和商业化的基础原料。

Forward-Looking Statements

前瞻性陈述

This press release contains forward-looking statements under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding Teknova’s expectations on the timing and completion of the offering and the anticipated use of proceeds therefrom. Forward-looking statements can often be identified by such words as 'will,' 'expects,' 'plans,' 'believes,' 'intends,' 'estimates,' 'projects,' 'continue,' 'potential' or other similar words or expressions.

本新闻稿包含根据1995年美国《私人证券诉讼改革法》的“安全港”条款所规定的前瞻性陈述，包括关于Teknova对发行时间安排和完成情况的预期以及所得款项预期用途的陈述。前瞻性陈述通常可以通过“将”、“预期”、“计划”、“相信”、“打算”、“估计”、“预测”、“继续”、“潜在”或其他类似词语或表述来识别。

Forward-looking statements are based on Teknova's current expectations. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and adversely and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: risks and uncertainties associated with market and other conditions and the satisfaction of customary closing conditions related to the proposed public offering and other risks that are described in Teknova’s most recent periodic reports filed with the Securities and Exchange Commission, including Teknova’s Annual Report on Form 10-K for the year ended December 31, 2025 and subsequent Quarterly Reports on Form 10-Q, including the risk factors set forth in those filings.

前瞻性陈述基于Teknova当前的预期。前瞻性陈述受各种风险和不确定性的影响，这些风险和不确定性可能导致实际结果出现重大不利差异，因此不应将已报告的结果视为对未来业绩的指示。这些风险和不确定性包括但不限于：与市场及其他状况相关的风险和不确定性、与拟议公开发行相关的惯常交割条件的满足情况，以及Teknova向美国证券交易委员会提交的最新定期报告（包括截至2025年12月31日的年度10-K表报告及随后的季度10-Q表报告）中所述的其他风险，包括这些文件中列明的风险因素。

These forward-looking statements speak only as of the date hereof. Teknova disclaims any obligation to update these forward-looking statements, except as required by applicable law. .

这些前瞻性陈述仅截至本文所述日期有效。Teknova 声明不承担任何更新这些前瞻性陈述的义务，除非适用法律另有要求。

Contacts:

联系人：

Investor Contact

投资者联系

Matt Lowell

马特·洛厄尔

Chief Financial Officer

首席财务官

matt.lowell@teknova.com

matt.lowell@teknova.com

+1 831-637-1100

+1 831-637-1100

Media Contact

媒体联系人

Jennifer Henry

詹妮弗·亨利

Senior Vice President, Marketing

营销高级副总裁

jenn.henry@teknova.com

jenn.henry@teknova.com

+1 831-313-1259

+1 831-313-1259

This press release was published by a CLEAR® Verified individual.

本新闻稿由一位经 CLEAR® 验证的个人发布。